- Alliqua Biomedical Inc ALQA shares tumbled 31.2 percent to $0.430. Alliqua BioMedical priced its 9.375 million share offering at $0.40 per share.
- Atossa Genetics Inc ATOS shares dipped 26.1 percent to $0.806 after the company reported the pricing of its $4,000,000 public offering.
- Ritter Pharmaceuticals Inc RTTR shares dipped 22.8 percent to $1.51 after the company reported topline results from its Ph2b/3 study for lactose intolerance treatment RP-G28.
- New Concept Energy, Inc. GBR shares fell 21.9 percent to $1.68.
- Diffusion Pharmaceuticals Inc DFFN shares dropped 21.1 percent to $3.93.
- Sunshine Heart Inc SSH declined 16.9 percent to $1.92. Sunshine Heart reported that it has received Nasdaq listing extension.
- Highpower International Inc HPJ shares fell 16.3 percent to $4.10.
- Catalyst Biosciences Inc CBIO shares tumbled 15.1 percent to $12.75 after surging 179.52 percent on Tuesday.
- Pernix Therapeutics Holdings Inc PTX dropped 14.2 percent to $3.48. Pernix Therapeutics reported a Q4 loss of $86.1 million.
- Quorum Health Corp QHC shares declined 13.5 percent to $5.51 after the company posted disappointing Q4 results.
- Takung Art Co Ltd TKAT dropped 13 percent to $8.30. Takung is expected to report 2016 financial results on March 29.
- Viewray Inc VRAY shares fell 6 percent to $8.12 after declining 8.76 percent on Tuesday.
- MoSys Inc. MOSY shares declined 5.3 percent to $2.32 as the company posted a wider-than-expected quarterly loss.
- USG Corporation USG dropped 4.5 percent to $32.22. Macquarie downgraded USG from Outperform to Neutral.
- F5 Networks, Inc. FFIV fell 4 percent to $141.29. Deutsche Bank downgraded F5 Networks from Hold to Sell.
- Skechers USA Inc SKX shares declined 3.1 percent to $29.05. Susquehanna downgraded Skechers from Positive to Negative.
- Depomed Inc DEPO shares fell 3 percent to $13.81. Depomed reported a cooperation agreement with Starboard Value LP. The company also issued a weak Q1 sales forecast.
- Dave & Buster's Entertainment, Inc. PLAY fell 2 percent to $60.96. Dave & Buster's reported better-than-expected earnings for its fourth quarter, but issued cautious outlook for 2017.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
